Aman's Global Market Intelligence

Executive dashboard

S&P 500 · Fri7,711.76−0.25%

Nasdaq Composite26,402.42−0.52%

Dow53,559.99−0.02%

Russell 20002,972.37−1.39%

VIX14.43−0.55%; low

U.S. 2Y / 10Y4.34% / 4.73%+14 / +6 bp

Dollar index99.677+0.52%

WTI / Gold$83.40 / $4,529.90−0.16% / −1.73%

Nikkei / Hang Seng66,406 / 25,585+1.34% / −1.63%

Shanghai Composite3,952.18+1.81%

Euro STOXX 50 / DAX6,485.67 / 26,569.99+0.58% / +1.66%

FTSE 10010,824.26+0.07%

1 · Duration

Rates are Monday's first filter

Chair Warsh's Friday speech emphasized price stability and called short-term rates the predominant dual-mandate tool. The official curve moved to 4.34%/4.73% for 2Y/10Y, with the front end up more. This is unfavorable for small caps, quantum and pre-profit biotech until yields confirm a reversal. Fed speech · Treasury

2 · Breadth

Index calm hid thematic damage

S&P −0.25% and VIX 14.43 looked calm, but Russell fell 1.39%; NVDA/VRT lost about 4.5%, MRVL 10.3%, and the tracked quantum incumbents 5%–8%. Low VIX does not hedge single-stock event gaps. Russell data · Cboe

3 · Calendar

AVGO is the week's thematic fulcrum

Broadcom is listed after Wednesday's close, between MongoDB Tuesday and Ciena/Zscaler/UiPath/DocuSign Thursday. AVGO can reset expectations for custom silicon, networking and AI capex; vendor EPS consensus is not company guidance. Nasdaq Sep. 2 calendar

Market drivers: Sunday outlook

Macro, central banks and geopolitics

Rates: Friday's +14 bp 2Y move was larger than the +6 bp 10Y move. Monday risk improves only if the front end retraces rather than merely if headline indices open green. Treasury XML
Dollar/real-rate signal: DXY rose 0.52% and gold fell 1.73%; oil was nearly flat. That cross-asset mix supports a policy/discount-rate interpretation rather than an energy shock. DXY · gold
Coming macro: BEA confirms July U.S. trade for Sep. 3 at 08:30 ET / 14:30 CEST. The FOMC meets Sep. 15–16 with projections. At 08:30 Italy, many U.S. releases have not occurred; do not trade unsourced previews as facts. BEA · Fed
Geopolitics: no new material geopolitical claim is promoted from weekend headline aggregation without a reliable primary or top-tier confirmation. Tariffs/export controls remain standing risks for semiconductors, not asserted fresh catalysts.

Earnings, regulation and rotation

NVIDIA: company results confirm $96.2B Q2 revenue (+106% y/y), $89.0B data-center revenue (+117%), and $108.0B ±2% Q3 revenue guidance with no China data-center compute revenue assumed. Friday's 4.57% decline says expectations and rates matter despite exceptional growth. NVIDIA · 10-Q
Marvell: Friday's 10.28% drop followed record $2.739B quarterly revenue and a $3.150B ±5% next-quarter guide. Its Aug. 28 10-Q is the newest non-insider filing found at cutoff; the selloff is an expectations warning, not proof AI demand disappeared. 10-Q
Quantum: Pasqal's primary filing verifies only completion of the combination and PSQL/PSQLW listing. The +96.81% first-day move is price discovery, not a technical or commercial milestone. SEC 6-K
Rotation: Friday favored large European benchmarks and defensive mega-cap pharma relative to U.S. small caps/speculation. Confirmation requires another session; one day is not a durable factor regime.

Theme dashboards

AI · repair required

Great fundamentals, damaged setups

Relative leader: CRM +1.57% while Nasdaq fell. Laggards: MRVL −10.28%, NVDA −4.57%, VRT −4.53%, CRDO −3.12%, ANET −2.84%.
Catalyst: AVGO Wednesday; CIEN, ZS and PATH Thursday. Watch custom silicon, networking, backlog, margins and capex commentary—not merely headline EPS.
Risk: 4.73% 10Y, high embedded expectations, export restrictions, concentration, power/cooling bottlenecks and vertical gap failures.

Quantum · extreme risk

No weekend commercial de-risking

Friday: PSQL +96.81% debut versus IONQ −7.68%, QUBT −5.78%, RGTI −5.17%, QBTS −5.08%.
Verified: SEC confirms PSQL listing; IONQ's latest 8-K covers directors and warrant expiration, not bookings, error rates or fault tolerance. IONQ 8-K
Risk: early commercialization, cash burn, dilution, architecture uncertainty, float/warrants and severe squeeze/reversal risk. Borrow and fees are unknown.

Peptide biotech · evidence wait

Clinical registry, not rumor

Friday: LLY −0.13%, NVO −1.41%, small-cap VKTX −5.02%; Lilly was relatively defensive, not bullish confirmation.
TRIUMPH-2: completed Phase 3 randomized double-blind trial, actual n=1,152. Primary measures are body-weight percent change and AHI change in a subset at week 80. Registry has no posted result statistics at cutoff. NCT05929079
Risk: efficacy, GI/other safety, discontinuation, manufacturing, reimbursement, competition, financing and binary readouts.

Ranked ideas — conditional Monday setups; quotas are ceilings

1Conditional bullish

CRM · Salesforce (NYSE)

Risk class: large-cap enterprise cloud; post-earnings gap / very high volatility. Classification: relative-strength base only. Applicable horizon: day trade and 1–4 week swing; 3–12+ months only after recurring growth and FCF review. Direction uncertain.

Thesis/catalyst: CRM closed $256.00, +1.57%, preserving Thursday's large gap while Nasdaq fell. The week's cloud earnings can provide read-through.

Evidence / counterargument: exchange-session data show the two-day relative-strength hold. Counter: the chart is vertically extended; gap support can fail, rates rose, and any one-off investment benefit is not recurring cloud demand.

Entry/confirmation: require a calm $252–256 base and break of Friday's range with volume plus positive software breadth. No Monday gap chase. Invalidation/downside: close below $248; $240 is next reference and gaps can skip stops. Key risks: valuation, rates, competition, execution, AI monetization quality and gap reversal. price

Thesis Confidence 71

Risk 91

Opportunity 60

1Avoid / failed-rebound bearish

PSQL · Pasqal Holding (Nasdaq)

Risk class: newly listed de-SPAC quantum; extreme price-discovery/liquidity risk. Classification: avoid chasing; bearish only after confirmed failed rebound. Applicable horizon: day observation only; 1–4 weeks wait for structure; no 3–12+ month call without filings and fundamentals. Direction highly uncertain. Short loss is unlimited.

Thesis/catalyst: first-day close $19.11, +96.81% against the $9.71 reference after combination close. Listing/float dynamics are not commercial validation.

Evidence / counterargument: SEC confirms listing and symbols; price feed confirms the move. Counter: scarce-float momentum can continue far beyond fundamentals, and future neutral-atom milestones could improve value.

Entry/confirmation: no blind short. Bearish only after a break below $17 followed by a failed reclaim; simplest action is avoid. Invalidation/downside: bearish view invalid above $20.10 on sustained volume. Key risks: unknown effective float here, halts, warrants, squeeze, dilution and limited history. Borrow/fees not sourced. SEC · price

Thesis Confidence 78

Risk 100

Opportunity 38

2Avoid pending stabilization

IONQ · IonQ (NYSE)

Risk class: speculative quantum; high valuation, cash-burn and event risk. Classification: avoid, not an immediate short. Applicable horizon: 1–4 week watch; 3–12+ months only with commercial/unit-economics proof. Direction uncertain. Short loss is unlimited.

Thesis/catalyst: IONQ fell 7.68% to $39.20 after Thursday's rebound. The latest 8-K concerns directors and warrant expiration—not revenue, bookings or technical performance.

Evidence / counterargument: SEC and Yahoo independently establish filing type and price. Counter: a verified contract/hardware milestone or speculative breadth rebound could reverse the decline sharply.

Entry/confirmation: no long until reclaim above $42.46 with positive quantum breadth; avoidance strengthens below $38. Invalidation/downside: avoidance expires above $44.86. Key risks: cash burn, dilution, commercialization, architecture competition, rates, volatility and squeeze. Borrow/fees unknown. SEC · price

Thesis Confidence 74

Risk 98

Opportunity 42

No second or third bullish idea and no third bearish idea: closed markets, rising rates and broken theme breadth leave no compelling additional opportunity. Waiting is a valid position.

Watchlist — five names

Ticker / exchange / risk class	Classification & horizon	Thesis, catalyst & counterargument	Confirmation, invalidation & risks	C / R / O
Watch AVGO Nasdaq · mega-cap custom silicon/networking; event-gap risk	Event watch; day/swing after Sep. 2 results; 3–12 months on FCF/guidance.	$368.79, −0.74%. Week's key AI ecosystem read-through. Counter: high expectations; Nasdaq's $2.83 EPS consensus is vendor data, not guidance.	Wait for results/base; above $372 constructive, below $360 weakens. Event gap, leverage, customer concentration, rates.	79 / 96 / 63
Watch NVDA Nasdaq · mega-cap; post-earnings/high expectations	Gap repair; day/swing after base; long term on growth/margins/FCF.	$217.55, −4.57% despite $108B ±2% guide. Counter: $96.2B quarter and +117% data-center growth are exceptional.	Reclaim $220 then $225; below $214 weakens. China/export, valuation, margin, rates and gap risk.	91 / 91 / 58
Watch VRT NYSE · large-cap/high-beta AI power & cooling	Broken setup; swing only after repair; long term on backlog/margins/FCF.	$257.08, −4.53%; prior setup stopped. Counter: structural data-center power demand remains plausible.	Reclaim $263 then $269; below $255 worsens. Capex timing, execution, valuation, rates.	77 / 88 / 51
Watch ANET NYSE · large-cap/high-valuation networking	Failed breakout; swing after repair; long term on revenue and FCF.	$195.38, −2.84%. AVGO may reset networking read-through. Counter: concentration/high multiple can outweigh sector demand.	Reclaim $197 then $202.25; below $193 weakens. Concentration, competition, valuation, rates.	73 / 85 / 49
Watch LLY NYSE · mega-cap pharma; clinical/regulatory binary risk	Relative-strength watch; 1–4 weeks; 3–12 months on franchise/data. Not a pre-readout trade.	$1,174.61, −0.13%. TRIUMPH-2 completed Phase 3, n=1,152; no results posted. Counter: valuation and unknown efficacy/safety statistics.	Require healthcare-relative strength and reclaim $1,180; below $1,150 weakens. Safety, discontinuation, reimbursement, competition, manufacturing.	82 / 75 / 57

C / R / O = Thesis Confidence / Risk / Opportunity. Confidence measures evidence quality, never guaranteed outcome probability.

Changes versus the 2026-08-29 report

Regime unchanged: neutral/risk-off under the surface. There is no new cash session, executable futures indication or verified primary catalyst sufficient to upgrade Friday's rate/breadth warning.
Ideas unchanged, deliberately: CRM remains the sole conditional long; PSQL and IONQ remain avoids/confirmation-only bearish setups. Levels are frozen rather than optimized with hindsight.
Sunday emphasis shifts to catalysts: AVGO's Sep. 2 report is the dominant AI infrastructure event, with MDB Tuesday and CIEN/ZS/PATH/DOCU Thursday.
Primary-source refresh: live SEC submissions showed no newer material operating filing for NVDA, MRVL or IONQ beyond the filings already analyzed. PSQL's 6-K still verifies listing mechanics, not fundamentals.
Clinical stance unchanged: live ClinicalTrials.gov confirms TRIUMPH-2 completed with n=1,152 but no results module/statistics; no anticipatory efficacy claim is made.

Important catalysts: next 7–30 days

Sun. Aug. 30 evening U.S. time — futures reopen
First tradable read on weekend risk. Treat the opening as thin and provisional; require cash-market breadth Monday. No Sunday-morning futures quote is presented.

Sep. 1 · after U.S. close — MongoDB earnings
Database/cloud consumption and AI-workload read-through. Nasdaq lists $0.08 EPS consensus from nine estimates; not company guidance. Nasdaq

Sep. 2 · after U.S. close — Broadcom and HPE earnings
AVGO is the key custom-silicon/networking event; HPE adds enterprise infrastructure context. Nasdaq lists $2.83 and $0.82 EPS consensus. Nasdaq

Sep. 3 · 14:30 CEST — July U.S. trade balance
BEA schedule confirmed. Tariff/trade effects can move dollar, rates and cyclicals. BEA

Sep. 3 · earnings — Ciena pre-market; Zscaler, UiPath, DocuSign after close
Networking, cybersecurity, automation and cloud-software read-throughs. Timing may change. Nasdaq

Sep. 10 / Oct. 1 — NVIDIA dividend record / payment
Company release states $0.25 quarterly dividend, record Sep. 10 and payment Oct. 1. Date-certain but not a major valuation catalyst. NVIDIA

Sep. 15–16 — FOMC + Summary of Economic Projections
Largest 30-day duration event; projections and press conference can reprice all three themes. Federal Reserve

Peptide pipeline — date not asserted
TRIUMPH-2 is complete, but no result statistics or public readout date are posted. No Lilly efficacy, safety or regulatory outcome is assumed. Registry

Bottom line by horizon

Day trade

Bias: neutral/risk-off until Monday breadth improves. CRM only after a stable $252–256 base; do not chase or blind-short PSQL.

Biggest risk: weekend gap and continuation in yields. Invalidation: tactical caution eases if semis reclaim Friday ranges while 2Y/10Y retreat; it strengthens if Russell loses 2,970 and NVDA loses $214.

1–4 week swing

Bias: high cash/selectivity ahead of AVGO and FOMC. Broken VRT/ANET/NVDA structures must repair; quantum and small-cap biotech need evidence.

Biggest risk: 4.73%+ 10Y and saturated earnings expectations. Invalidation: S&P gains accompanied by Russell/semiconductor breadth and repaired AI charts would upgrade the regime.

3–12+ month investment

Bias: favor profitable AI infrastructure only after valuation/FCF work; demand commercial proof in quantum and full statistical/regulatory evidence in peptide biotech.

Biggest risk: sticky inflation, peak capex, dilution or failed clinical endpoints. Invalidation: durable disinflation plus verified order and FCF acceleration supports more duration exposure.

Data quality & methodology

Timestamp/session: generated Sunday 08:30:58 CEST; research cutoff 08:29 CEST. All dashboard prices are Aug. 28 closes. Treasury is the official Aug. 28 curve. U.S., European and Asian cash markets are closed.
Mandatory live research completed: direct Yahoo chart API retrieval for 19 indices/futures/commodities; Treasury XML; four Google News RSS queries; four Nasdaq earnings calendars; SEC submissions for NVDA/MRVL/IONQ/RGTI; ClinicalTrials.gov v2 API; direct Fed calendar/speech, BEA schedule, NVIDIA IR and Pasqal SEC filing. These were more than five meaningful retrieval calls spanning market data, current news and primary sources.
Cross-checks: Sunday Yahoo pulls reproduce Friday S&P 7,711.76, Nasdaq 26,402.42, Dow 53,559.99 and Russell 2,972.37. Treasury independently fixes 2Y/10Y at 4.34%/4.73%. NVIDIA IR and SEC filing agree on the reported quarter; SEC submissions establish latest filing dates; Pasqal SEC verifies Nasdaq symbols.
Weekend-news discipline: Google News RSS was screened through 08:29 CEST. Most fresh items were opinion/listicle or secondary commentary; none was promoted as a material fact without primary corroboration. No market-moving weekend primary release was found in the tracked themes by cutoff.
Source limitations: generic web search and web extraction each returned payment-required errors. Direct curl/API alternatives succeeded. BLS September schedule returned HTTP 403 on direct access, so no BLS date is asserted. Yahoo futures metadata contained Friday settlements only; because markets had not reopened, these are not labeled live. No “unavailable” material dataset is substituted with estimates.
Price/technical method: daily changes and levels use Friday regular closes and the prior frozen report. Futures settlement values are excluded from the dashboard to avoid implying weekend liquidity. Technical triggers are conditional references, not guaranteed fills; gaps can skip them.
Biotech method: trial phase, design, actual enrollment, endpoints and status come from ClinicalTrials.gov. With no results module/statistics, efficacy, safety, cash-runway change or regulatory timing is not inferred. LLY is mega-cap rather than a financing-dependent biotech; VKTX is explicitly small-cap/high binary exposure.
Scoring: Confidence is evidence quality, not probability. Risk rises with event gaps, duration, valuation, liquidity, leverage, warrants, dilution and binary exposure. Opportunity balances evidence, asymmetry and timing.

Sources

Research disclaimer: Research and paper-tracking only—not individualized, guaranteed, fiduciary, legal or medical advice. The initial two weeks are paper-tracking. Prices can gap beyond invalidation levels; shorts can lose more than invested. Verify live quotes, liquidity, taxes and suitability independently.